Tackling challenges to tuberculosis elimination: Vaccines, drug-resistance, comorbidities

Matthias Ingo Paul Gröschel

    Onderzoeksoutput

    1527 Downloads (Pure)

    Samenvatting

    Despite being an ancient disease, tuberculosis causes more deaths than any other infection by a single agent. The current goal by the global public health community is to end tuberculosis by 2035. However, lack of an effective vaccine, emerging drug-resistances to important medicines, and comorbidities and coinfections emerging during antimicrobial treatment hamper elimination of tuberculosis. This thesis aims to tackle these challenges by i) describing the design and evaluation of a novel tuberculosis vaccine candidate that is more effective in protecting against tuberculosis infection in animal models than the currently used BCG vaccine; ii) testing an improved diagnostic algorithm to assess resistance to Ethambutol, a first-line drug; iii) checking the feasibility of glucose testing among difficult-to-reach tuberculosis patients, to check for diabetes; and to elucidate the population structure and biology of Stenotrophomonas maltophilia, an important emerging opportunistic pathogen relevant in the context of tuberculosis.
    Originele taal-2English
    KwalificatieDoctor of Philosophy
    Toekennende instantie
    • Rijksuniversiteit Groningen
    Begeleider(s)/adviseur
    • van der Werf, Tjip, Supervisor
    • Brosch, Roland, Supervisor, Externe Persoon
    • Niemann, Stefan, Supervisor, Externe Persoon
    Datum van toekenning1-apr.-2019
    Plaats van publicatie[Groningen]
    Uitgever
    Gedrukte ISBN's978-94-034-1433-1
    StatusPublished - 2019

    Citeer dit